Vikram Kansra brings 28 years of experience in the biotechnology industry to Vicero, including significant contributions to the development and approvals of Velcade® (multiple myeloma and mantle lymphoma), Entyvio® (ulcerative colitis and Crohn’s disease), Opdivo® (several cancers), Yervoy® (melanoma), Copiktra® (chronic lymphocytic leukemia and follicular lymphoma), Xpovio® (multiple myeloma and diffuse large B-cell lymphoma), Tazverik® (follicular lymphoma and epithelioid sarcoma), and others. With a focus on organizational excellence and full integration of high-performance teams with diverse backgrounds, Vikram’s leadership enables Vicero to successfully meet the demands of the regulatory and marketing environment, bringing next-generation nanobody therapies from the bench to the clinic and beyond.